INSMED INC Debt Securities, Available-for-sale, Unrealized Loss
INSMED INC (INSM) reported Debt Securities, Available-for-sale, Unrealized Loss of $700.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-20.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2025-02-20
- INSMED INC debt securities, available-for-sale, unrealized loss for the quarter ending 2023-06-30 was $100.00K, a 75.00% decline year-over-year.
- INSMED INC debt securities, available-for-sale, unrealized loss for the quarter ending 2023-03-31 was $200.00K, a 77.78% decline year-over-year.
- INSMED INC debt securities, available-for-sale, unrealized loss for the quarter ending 2022-12-31 was -$800.00K.
- INSMED INC debt securities, available-for-sale, unrealized loss for the quarter ending 2022-09-30 was $0.00.
- INSMED INC debt securities, available-for-sale, unrealized loss for fiscal 2023 was $700.00K, a 40.00% increase from fiscal 2022.
- INSMED INC debt securities, available-for-sale, unrealized loss for fiscal 2022 was $500.00K, a 150.00% increase from fiscal 2021.
- INSMED INC debt securities, available-for-sale, unrealized loss for fiscal 2021 was $200.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2023-12-31 | $700.00K 10-K · filed 2025-02-20 | |||
| 2023-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $300.00K 10-Q · filed 2023-08-03 | -$500.00K derived: sum of 3 quarters · filed 2024-02-22 | -$500.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2023-03-31 | $200.00K 10-Q · filed 2023-05-04 | -$600.00K derived: sum of 2 quarters · filed 2024-02-22 | -$600.00K derived: sum of 3 quarters · filed 2024-02-22 | -$200.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-12-31 | -$800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$800.00K derived: sum of 2 quarters · filed 2024-02-22 | -$400.00K derived: sum of 3 quarters · filed 2024-02-22 | $500.00K 10-K · filed 2024-02-22 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $400.00K derived: sum of 2 quarters · filed 2022-10-27 | $1.30M 10-Q · filed 2022-10-27 | |
| 2022-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.30M 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | $900.00K 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $200.00K 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |